The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
Open accessAbstract
Antipsychotic-induced extrapyramidal adverse effects are well recognized in the context of first-generation antipsychotic drugs. However, the introduction of second-generation antipsychotics, with atypical mechanism of action, especially lower dopamine receptors affinity, was met with great expectations among clinicians regarding their potentially lower propensity to cause extrapyramidal syndrome. This review gives a brief summary of the recent literature relevant to second-generation antipsychotics and extrapyramidal syndrome. Numerous studies have examined the incidence and severity of extrapyramidal syndrome with first- and second-generation antipsychotics. The majority of these studies clearly indicate that extrapyramidal syndrome does occur with second-generation agents, though in lower rates in comparison with first generation. Risk factors are the choice of a particular second-generation agent (with clozapine carrying the lowest risk and risperidone the highest), high doses, history of previous extrapyramidal symptoms, and comorbidity. Also, in comparative studies, the choice of a first-generation comparator significantly influences the results. Extrapyramidal syndrome remains clinically important even in the era of second-generation antipsychotics. The incidence and severity of extrapyramidal syndrome differ amongst these antipsychotics, but the fact is that these drugs have not lived up to the expectation regarding their tolerability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., & Davis, J. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 490
Lieberman, J. A., Tollefson, G., Tohen, M., Green, A. I., Gur, R. E., Kahn, R., McEvoy, J., Perkins, D., Sharma, T., Zipursky, R., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1396 · Cited by 404
Kapur, S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.6.553 · Cited by 396
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Posttraumatic stress disorder: a model of the longitudinal course and the role of risk factors.
Glazer, W. M. (2000) · PubMed · Cited by 340
Effects of Newer Antipsychotics on Extrapyramidal Function
Tarsy, D., Baldessarini, R. J., & Tarazi, F. I. (2002) · CNS Drugs · doi:10.2165/00023210-200216010-00003 · Cited by 313
Extrapyramidal side-effects of antipsychotics in a randomised trial
Miller, D. D., Caroff, S. N., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., Saltz, B. L., Riggio, S., Chakos, M. H., Swartz, M. S., Keefe, R. S. E., et al. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.050088 · Cited by 265
Godfrey‐Smith, P. (2003) · Cited by 201
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
Peluso, M. J., Lewis, S. W., Barnes, T. R. E., & Jones, P. B. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.101485 · Cited by 196
Woods, S. W., Morgenstern, H., Saksa, J. R., Walsh, B. C., Sullivan, M. C., Money, R., Hawkins, K. A., Gueorguieva, R. V., & Glazer, W. M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03890yel · Cited by 186
EPS Profiles: The Atypical Antipsychotics
Weiden, P. J. (2007) · Journal of Psychiatric Practice · doi:10.1097/00131746-200701000-00003 · Cited by 177
Hippius, H. (1989) · Psychopharmacology · doi:10.1007/bf00442551 · Cited by 168
Atypical Antipsychotics and Parkinsonism
Rochon, P. A., Stukel, T. A., Sykora, K., Gill, S., Garfinkel, S., Anderson, G. M., Normand, S.-L. T., Mamdani, M., Lee, P. E., Li, P., et al. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.16.1882 · Cited by 167
Pathophysiology of antipsychotic drug-induced movement disorders.
Casey, D. E. (2004) · PubMed · Cited by 159
Efficacy of atypicalv.typical antipsychotics in the treatment of early psychosis: meta-analysis
Crossley, N. A., Constante, M., McGuire, P. K., & Power, P. (2010) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.109.066217 · Cited by 157
Drug induced parkinsonism: a common cause of parkinsonism in older people
Thanvi, B., & Treadwell, S. D. (2009) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.073312 · Cited by 154
KUROKI, T., NAGAO, N., & NAKAHARA, T. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00910-2 · Cited by 146
Side Effects of Atypical Antipsychotics: Extrapyramidal Symptoms and the Metabolic Syndrome
Shirzadi, A. A., & Ghaemi, S. N. (2006) · Harvard Review of Psychiatry · doi:10.1080/10673220600748486 · Cited by 146
Margolese, H. C., Chouinard, G., Kolivakis, T., Beauclair, L., Miller, R. J., & Annable, L. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505001110 · Cited by 138
Antipsychotics in the Treatment of Schizophrenia
Tandon, R. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10075su1.01 · Cited by 137
Tardive dyskinesia and atypical antipsychotic drugs
CASEY, D. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00160-1 · Cited by 121
Tardive dyskinesias and antipsychotics: a review
Llorca, P., Chéreau, I., Bayle, F., & Lançon, C. (2002) · European Psychiatry · doi:10.1016/s0924-9338(02)00647-8 · Cited by 101
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Glazer, W. M. (2000) · PubMed · Cited by 99
Kasper, S. F., Tauscher, J. T., Kufferle, B., Barnas, C., Pezawas, L., & Quiner, S. (1999) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/pl00014189 · Cited by 96
Akathisia and second-generation antipsychotic drugs
Kumar, R., & Sachdev, P. S. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32832a16da · Cited by 92
Prevalence and severity of akathisia in patients on clozapine
Cohen, B. M., Keck, P. E., Satlin, A., & Cole, J. O. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90329-k · Cited by 91
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.
Remington, G. J., & Kapur, S. (1999) · PubMed · Cited by 88
How antidepressants help depression: mechanisms of action and clinical response.
Delgado, P. L. (2004) · PubMed · Cited by 85
A Risk-Benefit Assessment of Sulpiride in the Treatment of Schizophrenia
Mauri, M. C., Bravin, S., Bitetto, A., Rudelli, R., & INVERNIZZI, G. (1996) · Drug Safety · doi:10.2165/00002018-199614050-00003 · Cited by 74
Implications of the CATIE Trial on Treatment: Extrapyramidal Symptoms
Casey, D. E. (2006) · CNS Spectrums · doi:10.1017/s1092852900026651 · Cited by 69
Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients
Fenton, W. S., Blyler, C. R., Wyatt, R. J., & McGlashan, T. H. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.171.3.265 · Cited by 67
New and emerging treatments for symptomatic tardive dyskinesia
Rana, A. Q., Chaudry, Z. M., & Blanchet, P. J. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s32328 · Cited by 63
Typical and Atypical Antipsychotics – The Misleading Dichotomy
Fischer-Barnicol, D., Lanquillon, S., Haen, E., Zöfel, P., Koch, H. J., Dose, M., & Klein, H. E. (2008) · Neuropsychobiology · doi:10.1159/000135641 · Cited by 55
Rosenheck, R. A. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.106.035063 · Cited by 45
First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
(2012) · PsycEXTRA Dataset · doi:10.1037/e553822013-001 · Cited by 37
Extrapyramidal syndromes caused by antipsychotics
Poznic-Jesic, M., Ješić, A., Babovic-Filipovic, J., & Zivanović, O. (2012) · Medicinski pregled · doi:10.2298/mpns1212521p · Cited by 34
Novel Antipsychotics and Extrapyramidal Side Effects. Theory and Reality
Horáček, J. (2000) · Pharmacopsychiatry · doi:10.1055/s-2000-7660 · Cited by 32
Aripiprazole in a Patient Vulnerable to Side Effects
Dehning, S., Riedel, M. J., & Müller, N. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.625 · Cited by 28
Use or underuse of therapeutic guidelines in psychiatry?
Divac, N., Marić, N. P., Damjanović, A., Jovanović, A., Jašović‐Gašić, M., & Prostran, M. S. (2009) · PubMed · Cited by 21
Self-citationA Case of Acute Dystonia after Single Dose of Aripiprazole in a Man with Cocaine Dependence
Henderson, J. B., Labbate, L. A., & Worley, M. A. (2007) · American Journal on Addictions · doi:10.1080/10550490701375343 · Cited by 14
Cited by
Antipsychotics and glucose metabolism: how brain and body collide
Kowalchuk, C., Castellani, L. N., Chintoh, A., Remington, G., Giacca, A., & Hahn, M. K. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00164.2018 · Cited by 85
Citrome, L., Stensbøl, T. B., & Maeda, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1086269 · Cited by 63
Bimpisidis, Z., König, N., Stagkourakis, S., Zell, V., Vlcek, B., Dumas, S., Giros, B., Broberger, C., Hnasko, T. S., & Wallén-Mackenzie, Å. (2019) · eNeuro · doi:10.1523/eneuro.0066-19.2019 · Cited by 36
Yan, L., Zhou, J., Wang, D., Si, D., Liu, Y., Zhong, L., & Yin, Y. (2018) · Metabolomics · doi:10.1007/s11306-018-1375-3 · Cited by 36
Lornstad, M. T., Aarøen, M., Bergh, S., Benth, J. Š., & Helvik, A.-S. (2019) · BMC Geriatrics · doi:10.1186/s12877-019-1126-y · Cited by 24
Metadata
- Authors
- Divac, N., Prostran, M., Jakovcevski, I., & Cerovac, N.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-6
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2050584393
- Cited by
- 327
- References
- 44
- FWCI
- 11.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.